Literature DB >> 9681790

Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA.

R Bauernschmitt1, H Böhrer, S Hagl.   

Abstract

Administration of C1-esterase inhibitor (C1-INH) attenuates myocardial necrosis and sustains normal cardiac performance after myocardial ischemia and reperfusion in animal experiments. We report on our first experience of C1-INH application as rescue therapy in patients undergoing emergency surgical revascularization after failed percutaneous transluminal coronary angioplasty. Three patients were treated, because post-operative hemodynamic stabilization could not be achieved despite prolonged reperfusion periods, high-dose inotropic support, inodilators and aortic counterpulsation. As there was no surgical or medical option remaining, C1-INH was administered starting with a 2000 unit bolus, followed by 1000 U 12 and 24 h after surgery. C1-INH therapy resulted in rapid hemodynamic stabilization of all patients; weaning from aortic counterpulsation and epinephrine support was possible within 1 day. All patients survived and were discharged from hospital. In this group of patients suffering from severe reperfusion injury after coronary surgery, C1-INH seemed to be an effective adjuvant therapy to restore myocardial function by blocking the complement cascade. These results should encourage the performance of controlled studies on the effects of prophylactic C1-INH substitution therapy in patients undergoing coronary surgery at high risk conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681790     DOI: 10.1007/s001340050629

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat.

Authors:  P S Tsao; N Aoki; D J Lefer; G Johnson; A M Lefer
Journal:  Circulation       Date:  1990-10       Impact factor: 29.690

2.  Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.

Authors:  J E Gadek; S W Hosea; J A Gelfand; M Santaella; M Wickerhauser; D C Triantaphyllopoulos; M M Frank
Journal:  N Engl J Med       Date:  1980-03-06       Impact factor: 91.245

3.  Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs.

Authors:  B R Ito; D M Roth; R L Engler
Journal:  Circ Res       Date:  1990-03       Impact factor: 17.367

4.  Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion.

Authors:  G Horstick; A Heimann; O Götze; G Hafner; O Berg; P Böhmer; P Becker; H Darius; H J Rupprecht; M Loos; S Bhakdi; J Meyer; O Kempski
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

5.  Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion.

Authors:  M Buerke; T Murohara; A M Lefer
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

6.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins.

Authors:  D E Chenoweth; S W Cooper; T E Hugli; R W Stewart; E H Blackstone; J W Kirklin
Journal:  N Engl J Med       Date:  1981-02-26       Impact factor: 91.245

7.  Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence.

Authors:  A Farb; F D Kolodgie; M Jenkins; R Virmani
Journal:  J Am Coll Cardiol       Date:  1993-04       Impact factor: 24.094

Review 8.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

9.  Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury.

Authors:  R D Rossen; J L Swain; L H Michael; S Weakley; E Giannini; M L Entman
Journal:  Circ Res       Date:  1985-07       Impact factor: 17.367

10.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.

Authors:  H F Weisman; T Bartow; M K Leppo; H C Marsh; G R Carson; M F Concino; M P Boyle; K H Roux; M L Weisfeldt; D T Fearon
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

  10 in total
  13 in total

1.  Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke.

Authors:  M D Hill; P A Barber; J Takahashi; A M Demchuk; T E Feasby; A M Buchan
Journal:  CMAJ       Date:  2000-05-02       Impact factor: 8.262

Review 2.  Complement in ischemia reperfusion injury.

Authors:  Niels C Riedemann; Peter A Ward
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 3.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

Review 4.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

5.  Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits.

Authors:  Dorit Farfara; Emily Feierman; Allison Richards; Alexey S Revenko; Robert A MacLeod; Erin H Norris; Sidney Strickland
Journal:  Glia       Date:  2019-03-18       Impact factor: 7.452

6.  Circulating lectin pathway proteins do not predict short-term cardiac outcomes after myocardial infarction.

Authors:  C B Holt; J A Østergaard; S Thiel; T K Hansen; L Mellbin; P Sörensson; M Bjerre
Journal:  Clin Exp Immunol       Date:  2019-06-03       Impact factor: 4.330

7.  The effect of C1 inhibitor on myocardial ischemia and reperfusion injury.

Authors:  Fengxin Lu; Stacey M Fernandes; Alvin E Davis
Journal:  Cardiovasc Pathol       Date:  2012-06-16       Impact factor: 2.185

Review 8.  C1 inhibitor: molecular and clinical aspects.

Authors:  Marco Cicardi; Lorenza Zingale; Andrea Zanichelli; Emanuela Pappalardo; Benedetta Cicardi
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

Review 9.  Complement activation and cardiac surgery: a novel target for improving outcomes.

Authors:  Gregory L Stahl; Stanton K Shernan; Peter K Smith; Jerrold H Levy
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

Review 10.  The complement system in ischemia-reperfusion injuries.

Authors:  William B Gorsuch; Elvina Chrysanthou; Wilhelm J Schwaeble; Gregory L Stahl
Journal:  Immunobiology       Date:  2012-08-07       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.